Cantor Fitzgerald Cuts Price Target On This Cannabis MSO, But Touts Its Operations As 'One Of Best-In-Class'
Cantor Fitzgerald Cuts Price Target On This Cannabis MSO, But Touts Its Operations As 'One Of Best-In-Class'
Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) reported its financial results on Wednesday for the second quarter of fiscal 2022, revealing a 4% year-over-year increase in revenue to $218 million.
Cresco Labs Inc.（CSE: CL）（OTCQX: CRLBF）周三公布了2022财年第二季度的财务业绩，显示收入同比增长4％，达到2.18亿美元。
The transaction with Columbia Care Inc. (OTCQX:CCHWF) (NEO:CCHW) (CSE:CCHW) (FSE: 3LP) is proceeding as expected," Charles Bachtell, the company's CEO and co-founder, said in a press release adding that "the divestiture and regulatory processes are on track and we continue to anticipate a closing around year-end."
与哥伦比亚医疗公司（OTCQX: CCHWF）（NEO: CCHW）（CSE: CCHW）（FSE: CCHW）（FSE：3LP）的交易正在按预期进行。” 该公司首席执行官兼联合创始人查尔斯·巴赫特尔在一份新闻稿中补充说：“剥离和监管程序已步入正轨，我们仍然预计将在年底左右完成。”
Cantor Fitzgerald's analyst Pablo Zuanic addressed the company's earnings in his recent note, highlighting that that sequential revenue growth of 2% was below his estimate.
坎托·菲茨杰拉德的分析师巴勃罗·祖安尼奇在最近的报告中谈到了该公司的收益，强调2％的连续收入增长低于他的预期。
The Analyst
分析师
Zuanic retained Overweight ratings on both Cresco's and Columbia Care's stocks but lowered his 12-month price target for Cresco to $15 from $19 due to the reduced estimates, and disclosed a price target for Columbia of $8.37, up from $5.10.
Zuanic维持了对Cresco和Columbia Care股票的增持评级，但由于估计值下调，将Cresco的12个月目标股价从19美元下调至15美元，并披露哥伦比亚的目标股价为8.37美元，高于5.10美元。
The Thesis
论文
The analyst said the slight quarter-over-quarter revenue increase is "understandable" if taking into account Cresco's footprint and the fact that none of those states will go recreational in the second half of 2022.
这位分析师表示，如果考虑到Cresco的足迹以及这些州都不会在2022年下半年转向娱乐业这一事实，收入同比略有增长是 “可以理解的”。
However, he added that the "stock has optionality from several states in the east potentially going rec in the coming years."
但是，他补充说：“该股具有来自东部几个州的期权，未来几年可能会出现回升。”
Commenting on the deal to acquire its rival Columbia Care for $2.1 billion, which was announced in March, Zuanic said Cresco is now focused on closing the transaction, adding that "divestitures from the merger are seen raising gross proceeds north of $300 million."
Zuanic在评论3月份宣布的以21亿美元收购竞争对手哥伦比亚医疗的交易时说，Cresco现在正专注于完成交易，并补充说：“合并后的资产剥离预计将使总收益提高到3亿美元以上。”
The company "runs one of the best-in-class operations in the MSO space," the analyst said, referring to its revenue, store count as well as wholesale presence, and presence in key states.
这位分析师表示，该公司 “在MSO领域经营着一流的业务之一”，指的是其收入、门店数量和批发业务以及在主要州的业务。
CRLBF Price Action
CRLBF 价格走势
Cresco's shares traded $3.2% lower at $3.63 per share at the market close on Wednesday.
周三收盘时，Cresco的股价下跌3.2％，至每股3.63美元。
CCHWF Price Action
CCHWF 价格走势
Columbia Care's shares traded 3.19% lower at $1.82 per share at the market close on Wednesday.
周三收盘时，哥伦比亚医疗股价下跌3.19％，至每股1.82美元。
Benzinga Cannabis Capital Conference
本辛加大麻资本会议
Come and meet Pablo Zuanic, Charles Bachtell, and other extraordinary cannabis visionaries at the Benzinga Cannabis Capital Conference, which returns this fall in Chicago and stay at the historic Palmer House Hotel. Don't miss out on a chance to hear about future market forecasts and worldly advice on investing and finance from those embedded in the cannabis industry.
快来本辛加大麻资本会议上与巴勃罗·祖安尼奇、查尔斯·巴赫特尔和其他非凡的大麻远见卓识者见面，该会议将于今年秋天在芝加哥回归，入住历史悠久的帕尔默故居酒店。千万不要错过听取大麻行业内人士对未来市场预测以及有关投资和融资的世俗建议的机会。
Book your tickets HERE, and your room HERE.
在这里预订门票，在这里预订房间。
Photo: Courtesy of gerald by Pixabay
照片：由 Pixabay 提供 gerald